Lipocine (NASDAQ:LPCN) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCNGet Rating) in a research note released on Tuesday. The brokerage issued a buy rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of NASDAQ LPCN opened at $5.21 on Tuesday. Lipocine has a one year low of $3.30 and a one year high of $16.15. The business’s 50-day moving average price is $4.92 and its two-hundred day moving average price is $6.80. The company has a market capitalization of $27.09 million, a P/E ratio of -2.19 and a beta of 0.93.

Lipocine (NASDAQ:LPCNGet Rating) last released its quarterly earnings data on Friday, March 10th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter. On average, equities analysts anticipate that Lipocine will post -2.42 EPS for the current year.

Insider Buying and Selling

In related news, CEO Mahesh V. Patel bought 8,706 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were bought at an average cost of $5.03 per share, for a total transaction of $43,791.18. Following the completion of the acquisition, the chief executive officer now directly owns 107,418 shares in the company, valued at $540,312.54. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Mahesh V. Patel purchased 8,706 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was bought at an average price of $5.03 per share, for a total transaction of $43,791.18. Following the purchase, the chief executive officer now owns 107,418 shares in the company, valued at approximately $540,312.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mahesh V. Patel acquired 8,823 shares of the business’s stock in a transaction that occurred on Friday, March 24th. The stock was bought at an average cost of $5.44 per share, for a total transaction of $47,997.12. Following the completion of the purchase, the chief executive officer now directly owns 98,711 shares in the company, valued at approximately $536,987.84. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 20,705 shares of company stock worth $109,646. Corporate insiders own 5.00% of the company’s stock.

Institutional Trading of Lipocine

A number of institutional investors and hedge funds have recently modified their holdings of LPCN. Millennium Management LLC acquired a new position in Lipocine during the 2nd quarter worth $160,000. Renaissance Technologies LLC grew its holdings in Lipocine by 146.2% in the 3rd quarter. Renaissance Technologies LLC now owns 199,400 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 118,394 shares during the last quarter. Virtu Financial LLC bought a new position in Lipocine in the 3rd quarter worth approximately $42,000. Bailard Inc. acquired a new position in shares of Lipocine during the fourth quarter worth approximately $32,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Lipocine by 524.6% in the first quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 74,428 shares during the period. 12.18% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

(Get Rating)

Lipocine, Inc is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Read More

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.